Pilot and Feasibility Clinical Research Grants in Diabetes, Endocrine and Metabolic Diseases (R21)

archived

Purpose. This FOA, issued by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the Office of Dietary Supplements (ODS) of the National Institutes of Health, encourages exploratory/developmental clinical research related to the prevention or treatment of diabetes, obesity and endocrine and genetic metabolic diseases. The Pilot and Feasibility Clinical Research Grants Program is designed to allow initiation of exploratory, short-term clinical studies, so that new ideas may be investigated without stringent requirements for preliminary data. The short-term studies should focus on research questions that are likely to have high clinical impact. They can include testing a new prevention strategy, a new intervention, or unique combinations of therapies. A high priority is the use of such studies to help stimulate the translation of promising research developments from the laboratory into clinical practice in diabetes, endocrine diseases and genetic metabolic diseases, including cystic fibrosis. Mechanism of Support. This FOA will use the NIH Exploratory/Developmental (R21) grant mechanism. Funds Available and Anticipated Number of Awards. Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend upon the mechanism, numbers, quality, duration, and costs of the applications received.

High